Showing results (71-80 of 94) with videos related to
Sort By:
Pageof 10
Arthritis Care & Research|June 20, 2014
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritisAlan Kivitz, Ewa Olech, Michael Borofsky, et al.Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2020
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateMichael F Robinson, Nemanja Damjanov, Bojana Stamenkovic, et al.Rheumatology and Therapy|March 18, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical TrialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.Plos One|February 6, 2014
A randomized clinical trial to evaluate two doses of an intra-articular injection of LMWF-5A in adults with pain due to osteoarthritis of the kneeDavid Bar-Or, Kristin M Salottolo, Holli Loose, et al.The Journal of Rheumatology|March 1, 2003
Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trialArthur Kavanaugh, Mark Genovese, Jan Baughman, et al.RMD Open|August 28, 2019
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatmentMark C Genovese, Désirée van der Heijde, Yong Lin, et al.Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.Rheumatology and Therapy|October 1, 2025
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical TrialsAndrew Östör, Filip Van den Bosch, Kim Papp, et al.Nature Medicine|October 6, 2025
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialIain B McInnes, Laura C Coates, Philip J Mease, et al.Annals of the Rheumatic Diseases|December 24, 2016
Low immunogenicity of tocilizumab in patients with rheumatoid arthritisGerd R Burmester, Ernest Choy, Alan Kivitz, et al.Pageof 10